Recruiting in China · live from ClinicalTrials.gov

CAR-T cell therapy trials in China

CAR-T (chimeric antigen receptor T-cell) therapy re-engineers a patient's own immune cells to hunt cancer. China runs one of the largest CAR-T trial pipelines in the world, spanning multiple myeloma, lymphoma, leukemia, and a fast-growing set of solid-tumor programs.

For many international patients, a trial is a route to next-generation therapy that isn't yet approved — or is far more costly — at home. Enrollment in the investigational therapy is typically free; patients generally cover travel, lodging, and some routine care. Below are trials currently recruiting, pulled live from the public ClinicalTrials.gov registry.

282 car-t cell therapy trials recruiting

Each card links to full eligibility criteria and study locations. Not sure which fit? Ask Nora in the chat, or request a free review below.

NCT06828042

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases

RecruitingPHASE1PHASE2

🎯 Systemic Lupus Erthematosus, Systemic Sclerosis (SSc), Sjogren Syndrome📍 Beijing

NCT07048353

CD30 CAR-T in the Treatment of CD30 Positive Lymphoma

RecruitingEARLY_PHASE1

🎯 Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma📍 Wuhan

NCT07022964

CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas

RecruitingPHASE1PHASE2

🎯 T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)📍 Beijing, Shanghai

NCT07350863

U69-CART-Cells For R/R T-ALL

RecruitingPHASE1

🎯 Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma📍 Suzhou

NCT07105735

RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies

RecruitingPHASE1

🎯 Autoimmune Diseases Refractory to Standard Therapies📍 Nanjing

NCT06513429

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)

RecruitingNA

🎯 Refractory Systemic Lupus Erythematosus📍 Beijing

NCT07788118

A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

RecruitingPHASE1PHASE2

🎯 Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL)📍 Hangzhou

NCT06711146

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Moderate to Severe Active SLE Clinical Research

RecruitingEARLY_PHASE1

🎯 Systemic Lupus Erythematosus📍 Hangzhou

NCT07779018

CD19/CD22 CAR-T Consolidation in R/R Aggressive B-Cell Lymphoma After Second-Line Therapy

RecruitingPHASE2

🎯 Lymphoma📍 Beijing

NCT05477927

Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases

RecruitingPHASE1

🎯 Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises📍 Chengdu

NCT06947460

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

RecruitingPHASE1PHASE2

🎯 Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension📍 Beijing

NCT07490951

A Clinical Study of the Safety, Tolerability and Preliminary Efficacy of CD19/BCMA-targeted CAR-T Therapy in Refractory Autoimmune Diseases

RecruitingNA

🎯 Autoimmune Diseases📍 Wuhan

NCT06348797

Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC

RecruitingPHASE1

🎯 Small Cell Lung Cancer Extensive Stage📍 Chengdu

NCT07715136

BCMA-CD19 cCAR-T for the Treatment of Refractory Inflammatory Myopathy

RecruitingPHASE1

🎯 Inflammatory Myopathy📍 Chengdu

NCT07715630

In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma

RecruitingPHASE1

🎯 Relapsed or Refractory Multiple Myeloma (RRMM)📍 Kunming

NCT07188610

PA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma

RecruitingPHASE2

🎯 CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/Lymphoma📍 Hefei, Beijing, Guangzhou

NCT07681388

CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris

RecruitingNA

🎯 Pemphigus Vulgaris📍 Wuhan

NCT07234110

CD5 CART for the Treatment of Relapsed and Refractory CD5 Hematological Tumors

RecruitingNA

🎯 Relapsed and Refractory CD5 Hematological Tumors📍 Tianjin

NCT06946485

Universal Anti-CD70 CAR-T (CHT101) Cell Therapy for Relapsed Refractory Systemic Lupus Erythematosus

RecruitingEARLY_PHASE1

🎯 Systemic Lupus Erythematosus (SLE)📍 Nanjing

NCT07668557

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

RecruitingPHASE1

🎯 Acute Myeloid Leukemia (AML)📍 Nanchang

NCT07575971

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

RecruitingPHASE1PHASE2

🎯 B-cell Acute Lymphoblastic Leukemia📍 Beijing

NCT07645690

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

RecruitingEARLY_PHASE1

🎯 Unresectable or Metastatic Clear Cell Renal Cell Carcinoma📍 Beijing

NCT07652138

Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma

RecruitingPHASE1

🎯 Multiple Myloma, Newly Diagnosed Multiple Myeloma (NDMM)📍 Suzhou

NCT07575919

Targeted CD22/CD19 CAR-T Therapy for Consolidation in Standard-Risk B-ALL

RecruitingPHASE1PHASE2

🎯 B-cell Acute Lymphoblastic Leukemia📍 Beijing

NCT07072247

RN1201 Injection in the Treatment of Antibody-Mediated Diseases

RecruitingPHASE1

🎯 Refractory Immune-mediated Platelet Transfusion Refractoriness, Relapsed or Refractory Immune Thrombocytopenia📍 Suzhou

NCT07519187

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

RecruitingEARLY_PHASE1

🎯 Relapsed or Refractory Plasma Cell Neoplasms📍 Chengdu

NCT07344311

A Phase I Trial of A-CAR032 in Participants With mCRPC

RecruitingPHASE1

🎯 Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer📍 Beijing, Wuhan, Xuzhou

NCT07617285

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

RecruitingPHASE1

🎯 AML, Refractory/Relapse Acute Myeloid Leukemia📍 Beijing

NCT06937567

CDH17 CAR-T Therapy in Advanced Malignant Solid Tumors

RecruitingEARLY_PHASE1

🎯 Biliary Tract Cancer, Colorectal Carcinoma, Gastric Cancer, Metastatic📍 Hangzhou

NCT06326021

Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia

RecruitingPHASE1

🎯 Refractory/Relapsed Acute Myeloid Leukaemia📍 Shanghai, Chengdu, Beijing

NCT07303790

This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

RecruitingEARLY_PHASE1

🎯 Multiple Sclerosis📍 Hubei

NCT07587840

CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma

RecruitingPHASE2

🎯 Lymphoma📍 Beijing

NCT07002112

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

RecruitingPHASE1

🎯 Relapsed/Refractory B-cell Malignancies📍 Hefei, Beijing, Shijiazhuang

NCT07493044

An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma

RecruitingPHASE1

🎯 Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma📍 Guangzhou

NCT07454226

ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL

RecruitingNA

🎯 Ph-Like, Acute Lymphoblastic Leukemia📍 Tianjin

NCT07584889

Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

RecruitingPHASE1PHASE2

🎯 B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia📍 Shenzhen

NCT07259070

Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma

RecruitingPHASE1PHASE2

🎯 DLBCL, CLL, FL📍 Tianjin

NCT07261163

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

RecruitingPHASE2

🎯 Mantle Cell Lymphoma📍 Tianjin

NCT07337785

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

RecruitingEARLY_PHASE1

🎯 Relapsing or Refractory Multiple Sclerosis (MS), Myasthenia Gravis (MG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)📍 Wuhan

NCT06481735

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

RecruitingPHASE1PHASE2

🎯 Acute Lymphocytic Leukemia📍 Beijing, Changzhi, Tianjin

NCT06874946

Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL

RecruitingPHASE1PHASE2

🎯 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, T - Cell Lymphoma, PTCL📍 Beijing

NCT07564453

Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia

RecruitingPHASE2

🎯 B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative📍 Suzhou

NCT07249879

This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.

RecruitingPHASE1

🎯 Relapsed/Refractory Small Cell Lung Cancer📍 Beijing

NCT07528105

Allogeneic Anti-CD7 CAR-T for Type 1 Diabetes

RecruitingEARLY_PHASE1

🎯 T1DM - Type 1 Diabetes Mellitus📍 Shanghai

NCT07523529

Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

RecruitingPHASE1PHASE2

🎯 Advanced Unresectable, Metastatic📍 Shenzhen

NCT07523542

SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

RecruitingPHASE1PHASE2

🎯 REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis📍 Shenzhen

NCT07523555

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

RecruitingPHASE1PHASE2

🎯 Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia📍 Shenzhen

NCT04661020

CD19 CAR-T Therapy for Patients With Newly Diagnosed High-risk Large B-cell Lymphoma

RecruitingPHASE2

🎯 Large B-Cell Lymphoma (LBCL)📍 Hangzhou

NCT07509086

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

RecruitingPHASE2

🎯 Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia (PCL)📍 Changchun

NCT06880913

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

RecruitingPHASE1PHASE2

🎯 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma📍 Beijing

NCT07489989

Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.

RecruitingPHASE2

🎯 Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)📍 Beijing

NCT07489534

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

RecruitingPHASE2

🎯 Multiple Myeloma📍 Beijing

NCT06482905

Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

RecruitingPHASE1

🎯 High-grade Glioma, WHO Grade Ⅳ Glioma📍 Beijing

NCT07487597

Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors

RecruitingEARLY_PHASE1

🎯 Solid Tumor📍 Nanjing

NCT06658951

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

RecruitingNA

🎯 HER2-positive Advanced Malignant Solid Tumors📍 Zhengzhou

NCT07333677

In Vivo CAR-T for Refractory Graves' Disease

RecruitingEARLY_PHASE1

🎯 Graves' Disease📍 Shanghai

NCT07164560

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

RecruitingPHASE1

🎯 Refractory/Recurrent Peripheral T-cell Lymphoma📍 Hangzhou

NCT07475182

Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers

RecruitingEARLY_PHASE1

🎯 Advanced Solid Cancers📍 Haikou

NCT06688799

Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

RecruitingPHASE1PHASE2

🎯 Autoimmune Diseases📍 Beijing

NCT06316856

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

RecruitingPHASE1PHASE2

🎯 T-Cell Acute Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia📍 Beijing, Shanghai, Chengdu

Want help narrowing these down?

Send your diagnosis and treatment history and a coordinator will identify the car-t cell therapy trials you may actually qualify for — free, within 24 hours.

We share your details only with vetted treatment coordinators to check trial eligibility. No spam. See our privacy note.